China NMPA Product Recall - Implantable Cardioverter Defibrillator

Boston Scientific Corporation, through its wholly owned subsidiary Cardiac Pacemakers Incorporated and its reporting entity Boston International Medical Trade (Shanghai) Co., Ltd., has initiated a voluntary Class III recall for specific models and batches of its Implantable Cardioverter Defibrillator. This significant action was taken due to the identification of unapproved software upgrades affecting these devices. The recall, managed under the oversight of the National Medical Products Administration (NMPA) in China, highlights the importance of adherence to approved manufacturing and software modification protocols for medical devices. The primary issue revolves around software changes that did not undergo the necessary regulatory approval processes, potentially impacting device performance or safety. While the provided document does not specify inspection dates, the company proactively reported this non-compliance. The required action involves the immediate voluntary retrieval of all affected Implantable Cardioverter Defibrillator units from the market. Further detailed information regarding the precise product models, specifications, and batch numbers subject to this recall is made available in an accompanying 'Medical Device Recall Event Report Form'. This measure underscores the company's commitment to ensuring product safety and maintaining regulatory compliance within the medical device sector.